Longitudinal profile of circulating endothelial cells in post-acute coronary syndrome patients. (17th February 2023)

• Record Type: Journal Article
• Authors: de Bakker, Marie; Kraan, Jaco; Akkerhuis, K. Martijn; Oemrawsingh, Rohit; Asselbergs, Folkert W.; Hoefer, Imo; Kardys, Isabella; Boersma, Eric
• Is Part Of: Biomarkers. Volume 28:Number 2(2023)
• Page Start: 152
• Page End: 159
• Publication Date: 2023-02-17
• Subjects: Circulating endothelial cells -- acute coronary syndrome -- repeated measurements -- atherosclerosis -- vascular injury -- cardiovascular disease; Biochemical markers -- Periodicals; 610.28
• DOI: 10.1080/1354750X.2022.2162966
• Languages: English
• ISSNs: 1354-750X

Abstract

Abstract: Introduction Patients who have experienced an acute coronary syndrome (ACS) are at risk of a recurrent event, but their level of risk varies. Because of their close temporal relationship with vascular injury, longitudinal measurements of circulating endothelial cells (CECs) carry potential to improve individual risk assessment. Methods We conducted an explorative nested case-control study within our multicenter, prospective, observational biomarker study (BIOMArCS) of 844 ACS patients. Following an index ACS, high-frequency blood sampling was performed during 1-year follow-up. CECs were identified using flow cytometric analyses in 15 cases with recurrent event, and 30 matched controls. Results Cases and controls had a median (25 th -75 th percentile) age of 64.1 (58.1-75.1) years and 80% were men. During the months preceding the endpoint, the mean (95%CI) CEC concentration in cases was persistently higher than in controls (12.8 [8.2-20.0] versus 10.0 [7.0-14.4] cells/ml), although this difference was non-significant ( P = 0.339). In controls, the mean cell concentration was significantly ( P = 0.030) lower in post 30-day samples compared to samples collected within one day after index ACS: 10.1 (7.5-13.6) versus 17.0 (10.8-26.6) cells/ml. Similar results were observed for CEC subsets co-expressing CD133 and CD309 (VEGFR-2) or CD106 (VCAM-1). Conclusion Despite their close relation to vascular damage, no increase in cell concentrations were found prior to the occurrence of a secondary adverse cardiac event.